Teva completes acquisition of Actavis Generics

Erez Vigodman
Erez Vigodman

The Israeli pharmaceutical company is paying $33.43 billion in cash and $5.3 billion in shares.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Allergan plc (NYSE: AGN) today announced that Teva has completed its acquisition of Allergan’s generics business - Actavis Generics.

Allergan received $33.43 billion in cash and approximately 100 million Teva shares worth about $5.3 billion. Over the past few weeks Teva has raised more than $20 billion in debt in the US and Europe to finance the deal, which was first agreed in July 2015. It was only last week that Teva finally received US antitrust agreement for the merger.

Teva president and CEO Erez Vigodman said, “The acquisition of Actavis Generics comes at a time when Teva is stronger than ever- in both our generics and specialty businesses. Through our acquisition of Actavis Generics, we are creating a new Teva with a strong foundation, significantly enhanced financial profile and more diversified revenue sources and profit streams backed by strong product development engines in both generics and specialty. This is a platform that is expected to generate multi-year top-line and bottom-line growth as well as significant cash flow."

He added, “We are confident that we can realize the projected synergies and accretion inherent in this acquisition for our stockholders and quickly integrate Actavis Generics into Teva. Furthermore, as a result of our strengthened financial profile following this transaction, we will be even better positioned to reap the benefits of Teva’s R&D capabilities to support top-line growth and expand our portfolio across the business. The strong, combined company cash flow will allow for rapid deleveraging and give us the ability to continue capital allocation, with a focus on bolstering our specialty pipeline and product portfolio as well as strengthening shareholder returns.”

With the acquisition, Teva now has approximately 338 product registrations pending FDA approval and holds the leading position in first-to-file opportunities with approximately 115 pending ANDAs in the U.S. In Europe, after divestitures; Teva will have a pipeline capable of over 5000 launches across the region. In Teva growth markets including, Asia, Africa, Latin America, Middle East, Russia and CIS, there are now approximately 600 pending product approvals. Overall, Teva is planning for 1,500 generic launches globally in 2017.

Teva expects to achieve cost synergies and tax savings of approximately $1.4 billion annually by the end of 2019, by eliminating duplication and inefficiencies on a global scale and capturing economies of scale.

Published by Globes [online], Israel business news - www.globes-online.com - on August 3, 2016

© Copyright of Globes Publisher Itonut (1983) Ltd. 2016

Erez Vigodman
Erez Vigodman
French President Emmanuel Macron at the Paris Air Show in 2023 credit: Reuters Israel to scale down Paris Air Show presence

Due to President Emmanuel Macron's antagonism, Israel is reducing its presence at the exhibition, Ministry of Defense International Defense Cooperation Directorate (SIBAT) head Yair Kulas tells "Globes."

Jerusalem court cmplex credit: Zarhy Architects Tenders issued for two huge Jerusalem construction projects

The PFI tenders for the Gan Hotzvim tech campus and the courts complex include grants of NIS 1.7 billion for the winning bidders.

Israel Innovation Authority CEO Dror Bin Innovation Authority chief: Israel top for deep tech investment

Dror Bin told the Globes TECH IL conference that deep tech is the next wave for global tech and the rate of investment in Israel is the world's highest.

Gil Shwed and Nadav Zafrir credit: Menash Cohen With new CEO Check Point beats analysts in Q1

Revenue rose 6.5% and GAAP net profit rose 5% in Nadav Zafrir's first full quarter at the helm.

Nadav Zafrir credit: Niv Kantor Check Point CEO: We'll reinvent cybersecurity for the AI age

In his first interview since succeeding Gil Shwed, Nadav Zafrir was speaking at the Globes TECH IL Conference.

Tel Aviv light rail credit: Yossi Cohen Rishon Lezion to finance Red Line light rail extension

The Rishon Lezion Municipality will pay for part of the extension by marketing land above the planned underground depot.

Intel Haifa development center credit: Shutterstock Intel to cut 20% of workforce - report

"Bloomberg" reports that new CEO Lip-Bu Tan will announce the layoffs this week.

Healthee team credit: Healthee PR AI healthcare costs management co Healthee raises $50m

Healthee’s benefits and care navigation platform empowers employees and employers to make the most of their health benefits.

Former Shufersal CEO Itzik Abercohen credit: Eyal Izhar Competition Authority summons former Shufersal CEO to hearing

According to the indictment, Shufersal and Itzik Abercohen allegedly made public statements through which he attempted to reach arrangements to raise prices.

Reco founders Ofer Klein, Gal Nakash, and Tal Shapira credit: Elegant Photographics Israeli SaaS security co Reco raises $25m

The Tel Aviv-based company has developed a comprehensive application discovery engine capable of identifying and classifying over 50,000 applications, and providing visibility into an organization’s SaaS ecosystem.

Tel Aviv Stock Exchange credit: Tali Bogdanovsky TASE outperforms global markets in 2025

Boosted by the strong results of Israel's banks, the Tel Aviv Stock Exchange has demonstrated impressive resilience to domestic and foreign upheavals.

Metro credit: Bar Lavi Can Hyundai fill Metro vacuum created by China's exclusion?

The South Korean giant is reportedly eager to enter Israel's infrastructure sector but may not have the resources to dig the Metro tunnels.

Hero 120SF loitering munition  credit: Uvision Israeli firms to arm Germany with suicide drones

UVision's partnership with Rheinmetall and IAI's partnership with MBDA will help equip the German Army with an arsenal of loitering munitions.

Cipia Vision Credit: Company website Cipia Vision lays off 50% of workforce

The financially troubled Israeli auto-tech company raised NIS 68 million on the TASE in 2021 at a company valuation of NIS 354 million.

Israir aircraft credit: Moni Shafir Israir gets green light for Tel Aviv - New York flights

The US Department of Transport has approved US-Israel flights for the Israeli carrier.

Mentee Robotics founders credit: Mentee Robotics Shashua's Mentee to begin production of humanoid robots

Exclusive: Amnon's Shashua's Mentee Robotics will begin serial production next month of robots for use in logistics centers.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018